These GnRH-based nanoparticles significantly increased the accumulation of cisplatin in the primary and metastatic tumors (twice as much as with cisplatin alone), reduced drug delivery to kidneys, and improved its anticancer activity; decreasing tumor volume by 49% compared to free cisplatin (82). This evidence concerns the gene GNRH1 and neoplasm.